CA2228379A1 - Combined use of interleukin-10 and cyclosporin for immunosuppression therapy - Google Patents

Combined use of interleukin-10 and cyclosporin for immunosuppression therapy Download PDF

Info

Publication number
CA2228379A1
CA2228379A1 CA002228379A CA2228379A CA2228379A1 CA 2228379 A1 CA2228379 A1 CA 2228379A1 CA 002228379 A CA002228379 A CA 002228379A CA 2228379 A CA2228379 A CA 2228379A CA 2228379 A1 CA2228379 A1 CA 2228379A1
Authority
CA
Canada
Prior art keywords
interleukin
cells
csa
cyclosporin
mlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002228379A
Other languages
English (en)
French (fr)
Inventor
Waleed Tadmori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2228379A1 publication Critical patent/CA2228379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002228379A 1995-08-09 1996-08-06 Combined use of interleukin-10 and cyclosporin for immunosuppression therapy Abandoned CA2228379A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US205795P 1995-08-09 1995-08-09
US60/002,057 1995-08-09
US61995896A 1996-03-20 1996-03-20
US08/619,958 1996-03-20

Publications (1)

Publication Number Publication Date
CA2228379A1 true CA2228379A1 (en) 1997-02-20

Family

ID=26669861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002228379A Abandoned CA2228379A1 (en) 1995-08-09 1996-08-06 Combined use of interleukin-10 and cyclosporin for immunosuppression therapy

Country Status (5)

Country Link
EP (1) EP0845994A1 (ja)
JP (1) JPH11510806A (ja)
AU (1) AU712606B2 (ja)
CA (1) CA2228379A1 (ja)
WO (1) WO1997005896A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
EP1000626A1 (en) * 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Chemokine receptor antagonist and cyclosporin in combined therapy
JP3135532B2 (ja) 1998-09-29 2001-02-19 松下電送システム株式会社 ネットワークファクシミリ装置
US6577712B2 (en) 2000-04-07 2003-06-10 Telefonaktiebolaget Lm Ericsson (Publ) Distributed voice mail system
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
EP3062889A2 (en) 2013-11-01 2016-09-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
EP0662837B1 (en) * 1992-10-01 1999-05-19 Schering Corporation Use of il-10 to prevent insulin-dependent diabetes mellitus
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用

Also Published As

Publication number Publication date
AU6842296A (en) 1997-03-05
JPH11510806A (ja) 1999-09-21
EP0845994A1 (en) 1998-06-10
WO1997005896A1 (en) 1997-02-20
AU712606B2 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
CA2087525C (en) Adoptive immunotherapy with interleukin-7
Trinchieri Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
US9301979B2 (en) Method for attenuating immune response using mesenchymal stem cells and cytokines
RU2280255C2 (ru) Модуляция il-2- и il-15-опосредованных т-клеточных ответов
US6165785A (en) Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
EP0422186B1 (en) Use of oncostatin m for suppressing mhc antigens
CA2205430C (en) Method for making a medicament for treating secondary immunodeficiency
US11872250B2 (en) Methods for inducing an immune response by administering activated mesenchymal stem cells
WO2003087320A2 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
SK21195A3 (en) Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof
Zhong et al. Small peptide analogs to stromal derived factor–1 enhance chemotactic migration of human and mouse hematopoietic cells
US6074635A (en) T cell activation
NZ259584A (en) Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells
CA2228379A1 (en) Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
Bernengo et al. Immunomodulation and Sézary syndrome: experience with thymopentin (TP‐5)
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
Tokuda et al. The inhibitory effect of human interferon α on the generation of lymphokine-activated killer activity
Vallera et al. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2
Ulchaker et al. Interferon-γ production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to Interleukin-12
EP0561927B1 (en) Pharmaceutical compositions for the treatment of b-cell malignancies
AU643245B2 (en) A pharmaceutical preparation for the maturation of prothymocytes
Lotze et al. Interleukin-2 as a pharmacologic reagent
WO2000009150A2 (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
MXPA98001091A (en) Combined use of interleukin-10 and cyclosporine for immunosupres therapy
Jadus et al. Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead